Mucinous rectal tumors are more likely to be MSI-H, BRAF mutated and KRAS mutated which could potentially result in an impaired response to cytotoxic chemotherapy and EGFR inhibitors although this is only a hypothesis and needs to be confirmed prospectively with a much larger cohort. Here, KRAS is linked to rectal neoplasm.